Wockhardt Refuses To Comment On Formulations Demerger

Wockhardt has stayed quiet on reports that it is planning to spin off its formulations business into a separate operation and then sell a sizeable chunk of it to cut a massive debt load.

Spinning-Tops
Reports Suggest Wockhardt Is Considering Spinning Off Its Formulations Business • Source: Shutterstock

Wockhardt, one of India’s oldest drug firms, has refused to comment on media reports that it is aiming to demerge its formulations operation and then sell a significant minority stake in the business to reduce a mounting debt pile. The loss-making company said it would not respond to market “speculation.”

“We would like to state that being a responsible corporate, we do not comment on market rumour and/or speculation,” Wockhardt...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

Test

Wagner Adds Germany To Role As Stada Simplifies Structure

Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

Type:DisclosureDevelopments | Publication:GB | Section:Business | Paywall:Free — Article containing all Composer content for testing (Do not update)

 
• By 

Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.

More from Business

uygukgigo

 
• By 

Test

Podcast test

 
• By